Cerebral vascular calcium signaling in diabetic Alzheimer's disease-related dementias

Information

  • Research Project
  • 10117843
  • ApplicationId
    10117843
  • Core Project Number
    R03AG070784
  • Full Project Number
    1R03AG070784-01
  • Serial Number
    070784
  • FOA Number
    PAS-19-392
  • Sub Project Id
  • Project Start Date
    3/15/2021 - 3 years ago
  • Project End Date
    2/28/2023 - a year ago
  • Program Officer Name
    MACKIEWICZ, MIROSLAW
  • Budget Start Date
    3/15/2021 - 3 years ago
  • Budget End Date
    2/28/2023 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    3/12/2021 - 3 years ago
Organizations

Cerebral vascular calcium signaling in diabetic Alzheimer's disease-related dementias

Alzheimer's disease (AD) and AD-related dementias (ADRD) are the common incurable neurodegenerative even conditions characterized by progressive cognitive deterioration, memory decline and death. The major forms of ADRD include vascular contributions to cognitive impairment and dementia (VCID). In agreement, vascular dementia is the second most common form of dementia and the most frequent comorbidity with AD. Diabetes may production is a leading factor in the development of VCID; the ole of diabetes primarily occur due to the abnormal glucose metabolism and i ncreased reactive oxygen species (ROS) in cerebral vascular smooth muscle cells (CASMCs) r . In support, antioxidant therapies have shown promising results in protecting against diabetes-induced VCID and other dementias. the molecular mechanisms that link diabetes to the development of VCID remain to be elucidated, and current treatments for these diseases are neither always effective nor specific. The Based on our preliminary findings with previous work, in this project, we propose a novel central hypothesis that diabetes increases Rieske iron-sulfur protein (RISP)-mediated mitochondrial ROS, dissociates FK506 binding protein 12.6 (FKBP12.6) from type-2 ryanodine receptor (RyR2) to remove its inhibitory effect on RyR2 channel and induce Ca2+ release, which causes cerebral vasoconstriction and cerebral blood flow reduction, thereby leading to progressive memory loss, cognitive decline and VCID. To test this exciting hypothesis, we will conduct a series of mechanistic studies primarily by employing smooth muscle-specific RISP, RyR2, and FKBP12.6 knockout (KO) and/or overexpression (OE) mice with other complementary advanced experimental approaches to address the following specific questions (Specific Aims): Aim 1: Are the increased RISP-mediated mitochondrial ROS in CASMCs essential for VCID induced by diabetes? Aim 2: Is RyR2/FKBP12.6 complex dissociation a key consequence for the increased RISP-mediated mitochondrial ROS to mediate VCID induced by diabetes? The objectives of the present proposal are not only to enhance our understanding of the molecular mechanisms for VCID, ADRD devastating diseases. and AD, but also help to identify novel therapeutic targets for these common

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R03
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
    200000
  • Indirect Cost Amount
    126000
  • Total Cost
    326000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NIA:326000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    BINP
  • Study Section Name
    Brain Injury and Neurovascular Pathologies Study Section
  • Organization Name
    ALBANY MEDICAL COLLEGE
  • Organization Department
    PHYSIOLOGY
  • Organization DUNS
    190592162
  • Organization City
    ALBANY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    122083479
  • Organization District
    UNITED STATES